Literature DB >> 3121231

Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking.

R Kanarkowski1, K M Tornatore, R D'Ambrosio, M J Gardner, W J Jusko.   

Abstract

The effects of tobacco and oral contraceptive (OC) use (Ovral) on the pharmacokinetics of levonorgestrel (0.25 mg) and ethinyl estradiol (50 micrograms) were examined. Young women (n = 27) were grouped as follows: I: non-OC users/nonsmokers; II: OC users/nonsmokers; III: non-OC users/smokers; and IV: OC users/smokers. The apparent clearance of levonorgestrel in group I was 80.9 +/- 15.6 ml/hr/kg and the half-life was 19.3 hours. A significant decrease in levonorgestrel clearance was seen in the chronic OC users (groups II and IV). The apparent oral clearance of ethinyl estradiol was 1002 +/- 398 ml/hr/kg in group I and the half-life averaged 7.7 hours. Groups II and III showed decreased (not significant) clearance of ethinyl estradiol. Tobacco use had no effect on steroid pharmacokinetics in the non-OC users. Although chronic OC use did not affect ethinyl estradiol clearance, a joint effect of tobacco/OC use on enhancing clearance of ethinyl estradiol appeared to occur. A linear relationship was found between 24-hour trough serum concentrations and AUC values of both steroids that may facilitate population monitoring studies of OC exposure.

Entities:  

Keywords:  Behavior; Biology; Comparative Studies; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods--pharmacodynamics; Drug Interactions; Drugs; Endocrine System; Ethinyl Estradiol; Family Planning; Hormones; Levonorgestrel; Oral Contraceptives--pharmacodynamics; Physiology; Reproductive Control Agents; Research Methodology; Smoking--pharmacodynamics; Social Behavior; Studies; Treatment

Mesh:

Substances:

Year:  1988        PMID: 3121231     DOI: 10.1038/clpt.1988.7

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Smoking and recurrent attacks of acute intermittent porphyria.

Authors:  G Y Lip; K E McColl; A Goldberg; M R Moore
Journal:  BMJ       Date:  1991-03-02

2.  Estimating systemic exposure to levonorgestrel from an oral contraceptive.

Authors:  Cale N Basaraba; Carolyn L Westhoff; Malcolm C Pike; Renu Nandakumar; Serge Cremers
Journal:  Contraception       Date:  2016-12-30       Impact factor: 3.375

Review 3.  Transdermal patches: history, development and pharmacology.

Authors:  Michael N Pastore; Yogeshvar N Kalia; Michael Horstmann; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

Review 4.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 5.  Perspectives on variability in pharmacokinetics of an oral contraceptive product.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-07-27       Impact factor: 3.375

Review 6.  Drug interactions with tobacco smoking. An update.

Authors:  S Zevin; N L Benowitz
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 7.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

Review 8.  Oral contraceptives. Are drug interactions of clinical significance?

Authors:  G M Shenfield
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 9.  Clarification of contraceptive drug pharmacokinetics in obesity.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-08-16       Impact factor: 3.375

10.  Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 alpha-ethinyloestradiol. Relative activities of rat and human liver enzymes.

Authors:  S E Ball; L M Forrester; C R Wolf; D J Back
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.